A Study of Mirikizumab Solution (LY3074828) in Healthy Participants

Inclusion Criteria: * Are overtly healthy males or females as determined by medical evaluation including: * medical history * physical examination * clinical laboratory tests * ECG, and * vital signs. * Have clinical laboratory test results at screening and Day -1 within normal reference range. * Have a body mass index (BMI) within the range of 18.0 to 34.0 kilograms per square meter (kg/m²), inclusive. Exclusion Criteria: * Have significant allergies to humanized monoclonal antibodies or known allergies to mirikizumab, related compounds or any components of the formulation, or history of significant atopy. * Have significant previous or current history of comorbidities capable of significantly altering the absorption, metabolism, or elimination of drugs. * Have clinically significant multiple or severe drug allergies, or intolerance to topical corticosteroids, or severe post-treatment hypersensitivity reactions. * Are immunocompromised. * Intend to use over-the-counter or prescription medication, including herbal medications and traditional medications, within 7 days prior to dosing. * Have received treatment with biologic agents within 3 months or 5 half-lives, whichever is longer, prior to dosing. * Have previously received mirikizumab. * Have an abnormality in the 12-lead electrocardiogram (ECG). * Have clinically significant abnormalities in blood pressure, pulse rate, or body temperature. * Have a current or recent acute, active infection. * Have active tuberculosis (TB), or any history of active TB.